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Circulating levels of adiponectin, an adipocyte-secreted protein associated with cardiovascular and metabolic risk, are highly heritable.
To gain insights into the biology that regulates adiponectin levels, we performed an exome array meta-analysis of 265,780 genetic
variants in 67,739 individuals of European, Hispanic, African American, and East Asian ancestry. We identified 20 loci associated
with adiponectin, including 11 that had been reported previously (p < 2 3 107). Comparison of exome array variants to regional
linkage disequilibrium (LD) patterns and prior genome-wide association study (GWAS) results detected candidate variants (r2 > .60)
spanning as much as 900 kb. To identify potential genes and mechanisms through which the previously unreported association signals
act to affect adiponectin levels, we assessed cross-trait associations, expression quantitative trait loci in subcutaneous adipose, and
biological pathways of nearby genes. Eight of the nine loci were also associated (p < 1 3 104) with at least one obesity or lipid trait.
Candidate genes include PRKAR2A, PTH1R, and HDAC9, which have been suggested to play roles in adipocyte differentiation or
bone marrow adipose tissue. Taken together, these findings provide further insights into the processes that influence circulating adipo-
nectin levels.Introduction
Adiponectin is an adipose tissue-derived hormone that
affects energy homeostasis and may link adiposity with
the risk of type 2 diabetes (T2D), hyperinsulinemia, and
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adiponectin levels and metabolic syndrome, as well as
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analysis performed to date tested associations between
2.4 million variants, imputed to the HapMap reference
panel, in up to 35,355 individuals primarily of European
ancestry (83%) and identified 12 loci, including ADIPOQ
(MIM: 605441), which encodes the adiponectin protein,
and CDH13 (MIM: 601364), which encodes cadherin-13,
a receptor that binds to circulating adiponectin.14 A subse-
quent adiponectin GWAS meta-analysis in up to 18,079
East Asians, using HapMap-imputed variants, identified
one additional locus near WDR11-FGFR2 (MIM: 606417,
176943).19 These common genetic variants accounted for
only 5% of the variance in adiponectin levels.14,19,20
Further investigation into the genetic basis for adiponectin
levels and the associated loci would provide further insight
into the genetic architecture and biological processes influ-
encing adiponectin.
To discover and characterize candidate loci influencing
circulating levels of adiponectin in order to further under-
stand its role in insulin sensitivity and related traits, we
combined exome array association results of up to 67,739
individuals from four ancestries (60,465 European, 3,271
African, 2,568 East Asian, and 1,435 Hispanics) to conduct
the largest genetic analysis of adiponectin levels to date.
Exome-based association studies, containing mostly non-
synonymous variants (n ¼ 213,082, 80.2% of all variants
in the analysis), may potentially provide results with
more direct biological interpretability. However, nonsy-
nonymous variant associations do not constitute sufficient
evidence to implicate the target gene(s) underlying an
association signal.21 Therefore, we used extent of linkage
disequilibrium (LD), gene expression-variant association
data, and pathway analyses to suggest genes and mecha-
nisms through which the previously unreported variants
may act to affect adiponectin levels.Material and Methods
Study Design and Participants
Our meta-analysis consisted of 25 studies (28 datasets) comprising
up to 67,739 adult individuals (R18 years) of the following ances-
tries: (1) European (n% 60,465), (2) East Asian (n% 2,568), (3) Af-
rican American (n % 3,271), and (4) Hispanic (n % 1,435). All
participating institutions and coordinating centers approved this
project, and informed consent was obtained from all study partic-
ipants. In our primary discovery analyses, we combined data of all
ancestries for both sex-specific and sex-combined analyses
(Figure S1). Study-specific design, sample quality control, and
descriptive statistics are provided in Tables S1–S3.
Genotype Calling
Each of the 25 contributing studies followed a standardized proto-
col and performed genotype calling of variants on the Illumina
HumanExome Beadchip using the designated manufacturer’s soft-
ware. Study-specific quality control measures of the genotyped
variants were implemented before association analyses (Table
S2). We excluded variants with a call rate < 98%, Hardy Weinberg
equilibrium p< 13 106, or large allele frequency deviations fromTthe reference populations (>0.60 for all ancestry analyses and
>0.30 for ancestry-specific population analyses).
Statistical Analyses
We created residuals of adiponectin levels (in mg/mL) after
adjustment for age, body mass index (BMI), and principal com-
ponents (PCs, derived from GWAS data, variants with minor
allele frequency [MAF] > 1% on the exome array, or ancestry-
informative markers on the exome array), as well as any study-
specific covariates, using a linear regression model. For studies
with unrelated individuals, residuals were calculated separately
by sex; for family-based studies, sex was included as a covariate
in the model. Additionally, residuals for case-control studies
were calculated in case subjects and control subjects separately.
Finally, residuals were subjected to inverse normal transforma-
tion to obtain distributions with a mean of 0 and a standard de-
viation of 1, yielding approximately normally distributed trait
values for downstream analyses. In additional analyses per-
formed without adjustment for BMI and adjusted for fat percent-
age instead of BMI, results were similar (Figures S2–S5, Table S4)
with one additional locus detected in models unadjusted for
BMI (rs900399 in LEKR1 [MIM: 613536]); other signals became
less significant.
Each study performed single-variant association analyses be-
tween inverse normal-transformed adiponectin levels (adjusted
for age, sex, BMI, and other study-specific covariates) and exome
array variants, including up to 28,868 common (MAF R 5%)
and 236,912 low-frequency (1% % MAF < 5%) or rare (MAF <
1%) variants, using either RAREMETALWORKER or RVTEST (Table
S2).22,23 All analyses were performed in sex-combined and sex-spe-
cific groups, accounting for potential cryptic relatedness (kinship
matrix), in a linear mixed model.
We applied a centralized quality control procedure to individual
cohort association summary statistics using EasyQC24 to: (1) assess
adiponectin transformation, (2) compare allele frequency align-
ment to the 1000 Genomes Project phase 1 reference panel to
detect strand errors, and (3) examine quantile-quantile plots per
study to detect population stratification, cryptic relatedness, and
genotype biases.
Summary statistics were meta-analyzed using fixed-effects in-
verse-variance analyses in an all-ancestry, sex-combined, additive
model, and variant associations that reached p < 2 3 107 were
considered array-wide significant (Bonferroni corrected for multi-
ple testing; 0.05/265,780 variants).21,25,26 Meta-analyses were
carried out using RAREMETAL27 by two analysts at two sites in
parallel. For all significant variants identified in the meta-analyses,
we tested for differences between women-specific and men-spe-
cific beta estimates using EasyStrata.28 Each variant that reached
psexhet < 0.05/(number of variants tested) was considered signifi-
cant. In secondary analyses, we also performed analyses with adi-
ponectin levels unadjusted for BMI and with adiponectin levels
adjusted for fat percentage instead of BMI, as well as analyses strat-
ified by sex (Figures S2–S8).
For gene-based analyses, we applied the sequence kernel associ-
ation test (SKAT)29 and variable threshold (VT)30 gene-based
methods in RAREMETAL using two different sets of criteria (broad
and strict).26,31 These two sets of criteria were used to select vari-
ants with aMAF< 5%within each ancestry group based on coding
variant annotation from five prediction algorithms (PolyPhen2,
HumDiv and HumVar, LRT, MutationTaster, and SIFT). The broad
gene-based tests comprised of nonsense, stop-loss, splice site, and
missense variants annotated as damaging by at least one algorithmhe American Journal of Human Genetics 105, 1–14, July 3, 2019 3
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nonsense, stop-loss, splice site, and missense variants annotated
as damaging by all five algorithms. Statistical significance for
gene-based tests was set at a Bonferroni-corrected threshold of
p< 2.53 106 based on approximately 20,000 genes.32 As second-
ary analyses were nested and/or highly correlated with the pri-
mary analysis, we chose the same stringent Bonferroni-corrected
significance threshold for all analyses.
We also used the RAREMETAL R package to identify indepen-
dent association signals across all ancestries and European (sex-
combined and sex-specific) meta-analysis results. In 1 Mb win-
dows centered on each lead (most significantly associated) variant,
we performed sequential rounds conditioning on the lead variant
to identify additional signals at p < 2 3 107.
Assessment for Bias
To address possible collider bias33,34 in our significant association
results, we used the summary statistics from an exome-chip study
of BMI, a GWAS of body fat percentage, and our adiponectin re-
sults from models unadjusted for BMI or fat percentage.26 Our
principal aim was to exclude the possibility that some of the
discovered adiponectin-SNP associations are entirely driven by
the association of the SNPs and obesity traits correlated with
adiponectin levels. To this end, BMI and fat percentage-adjusted
associations were corrected for potential bias due to phenotypic
correlation between adiponectin levels and each covariate as
well as possible association between each variant and covariate.
Strength and significance of association with adiponectin unad-
justed, adjusted for BMI, or adjusted for fat percentage were
compared with each other, and those of covariates and corrected
statistics. Corrected effect sizes were estimated using the following
equation:33
bcorrected ¼ badiponectin adj: covariate þ

bcovariate 3 rcovariate 3 adiponectin

where rBMI x adiponectin ¼ 0.31 and rfat percent x adiponectin ¼
0.27.35
Associations with Cardiometabolic Traits
We evaluated each of the nine previously unreported loci that we
detect here for association in prior adiponectin GWAS meta-ana-
lyses from ADIPOGen14 and AGEN19 and with other cardiometa-
bolic traits and diseases. For these traits, we examined existing
genome- and exome-wide meta-analysis results from consortia
including GIANT (BMI26 and waist-to-hip-ratio adjusted for
BMI36), GLGC (total cholesterol, HDL, LDL, and triglycerides),25
T2D,21 and MAGIC (HbA1c, fasting insulin, fasting glucose,
2-hour glucose).37–40 We also examined the UK Biobank for associ-
ations with cardiometabolic traits and diseases. In addition, Phe-
noScanner was used to perform a PheWAS on all available traits,
plasma proteins, and metabolites. We report proteins and metab-
olites when the lead exome variant and the variant most strongly
associated with the protein or metabolite within 1 Mb exhibit
high pairwise LD (r2 > 0.80). We did not identify any plasma pro-
teins that met our criteria.
Annotation and Colocalization of Association Signals
with eQTL Data
We examined whether any of the lead exome-wide associated
variants were associated with expression (FDR < 1% for METSIM
for rigor; FDR < 5% for GTEx as available) of nearby transcripts
located within 1 Mb in subcutaneous or visceral adipose tissue4 The American Journal of Human Genetics 105, 1–14, July 3, 2019(eQTLs).41,42 Briefly, gene expression was measured in subcutane-
ous adipose tissue in 770 Finnishmale participants from theMeta-
bolic Syndrome in Men Study (METSIM) using the Affymetrix
U219 microarray. From GTEx v7, we used gene expression data
from 385 subcutaneous and 315 visceral adipose samples.
Variant-trait and eQTL signals may colocalize when the lead
exome variant and the variant most strongly associated with the
expression level of the corresponding transcript (eSNP) exhibit
high pairwise LD (r2 > 0.80). For such signals identified in the
METSIM eQTL data, we also further assessed colocalization using
reciprocal conditional analyses to test the association between
the lead exome variant and transcript level when the eSNP was
also included in the model, and vice versa; we reported exome-
wide and eQTL signals as colocalized if the association for the
eSNP was not significant (FDR > 1%) when conditioned on the
adiponectin-associated exome variant.
Gene Set Enrichment Analysis
We performed a gene set enrichment analysis based on the Euro-
pean summary statistics of variants from the adiponectin adjusted
for BMI association results using EC-DEPICT. EC-DEPICT, de-
signed for use in exome array analyses,26,43 assesses enrichment
for a group of 14,462 gene sets (including canonical pathways,
protein-protein interaction networks, and mouse phenotypes)
that have been ‘‘reconstituted’’ using large-scale co-expression
data. Briefly, enrichment p values were calculated using 2,000 per-
mutations of 378,141 European samples from the UK Biobank,
where only variants present on both the ExomeChip and UK
Biobank arrays were included for analysis.26,44 The input data
included genes directly containing the most significant nonsy-
nonymous coding variant per locus, where loci were defined
as51 Mb from the index variant. We performed EC-DEPICT ana-
lyses using variants with an association of p < 5 3 104 across (1)
all variants and (2) variants with MAF < 5%.We considered a false
discovery rate of less than 0.05 to be statistically significant.
We also performed a pathway analysis by applying PASCAL to
the European exome-wide summary statistics from the adiponec-
tin (adjusted for BMI) association results.45 The method derives
gene-based scores and subsequently tests for over-representation
of high gene scores in pre-defined biological pathways. For the
gene-based scores we performed both MAX and SUM estimations:
the former being more powerful when the association is driven by
a single variant in/near the focal gene, while the latter is preferred
in case of allelic heterogeneity. We used both standard pathway li-
braries and dichotomized (Z-score > 3) reconstituted gene sets
from DEPICT. A reference dataset from UK10K (TwinsUK46 and
ALSPAC47 studies, n ¼ 3,781) was used for LD estimation. Unlike
EC-DEPICT, p value thresholds were not used to select input vari-
ants from the exome-wide data. Variants with MAF < 1% in the
reference dataset were included in the analysis. To separate the
contribution of coding (nonsynonymous and synonymous) vari-
ants, we performed PASCAL analyses across (1) all variants and
(2) only coding variants. p < 5 3 105 was considered statistically
significant after Bonferroni correction for multiple testing with
1,000 independent pathways.Results
We conducted meta-analyses of single-variant association
summary statistics, including data from up to 67,739 indi-
viduals from 25 studies (Tables S1–S3) across four ethnic
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study performed single-variant association analyses adipo-
nectin adjusted for age, sex, and BMI and exome array
variants, and summary statistics from each dataset were
meta-analyzed using fixed-effects analyses in an all-
ancestry, sex-combined, additive model.21,25,26 In second-
ary analyses, we also examined adiponectin levels
unadjusted for BMI, adiponectin levels adjusted for fat
percentage instead of BMI, and models stratified by sex
(Figures S2–S8). Participants were broadly representative
of adults (age 18–95 years) of both sexes (51.2% male)
with a wide distribution of BMI and adiponectin levels (Ta-
ble S3).
Association Results
The primary sex-combined analysis of adiponectin levels
adjusted for BMI identified variants (p < 2.0 3 107) at
11 known loci (in/near LYPLAL1 [MIM: 616548], IRS1
[MIM: 147545], STAB1 [MIM: 608560], ADIPOQ, ARL15
[MIM: unknown]/FST [MIM: 136470], PDE3A [MIM:
123805], CLIP1 [MIM: 179838], DNAH10 [MIM: 605884],
CMIP [MIM: 610112], CDH13, and PEPD [MIM: 613230])
and 8 loci (in/near KIF9 [MIM: 607910], DALRD3 [MIM:
unknown], FAM13A [MIM: 613299], SLC39A8 [MIM:
608732], SNX13 [MIM: 606589], GIMAP7 [MIM: 616961],
RIC8B [MIM: 609147], and SLC38A8 [MIM: 615585]) (Ta-
bles 1 and S5; Figures 1, 2, S7, and S9). Lead variants at
each locus were primarily common (MAF R 5%), with
the exception of one low-frequency variant at SLC39A8
(rs13107325; MAF ¼ 4.7%) and one rare variant at
SLC38A8 (rs145119400; MAF ¼ 0.5%). An all-ancestry,
women-only analysis identified an additional locus
(rs1199354, OPLAH [MIM: 614243], MAF ¼ 10.1%) that
also exhibited significant sex heterogeneity (p ¼ 2.5 3
105; Table 1; Figure S10). Low to moderate levels of het-
erogeneity were detected among the lead variants at each
locus (Table S5). We further tested the association of adipo-
nectin levels with aggregated variants within each gene by
performing gene-based association tests; however, no addi-
tional loci were detected (Table S6).
To investigate the potential for collider bias in the adipo-
nectin analysis resulting from adjusting for a correlated
covariate, BMI, we investigated the behavior of variants
associated with adiponectin adjusted for BMI in analyses
of adiponectin without adjustment for BMI and analyses
of BMI alone, estimating the effect of bias. Nearly all of
the adiponectin-associated variants identified showed a
genuine effect on adiponectin levels, and any bias caused
by adjusting for BMI was minimal. Only one locus
(SLC39A8; rs13107325) exhibited potential pleiotropy
and/or a collider bias effect due to BMI adjustment (Table
S7). It is possible that applying rank-based inverse normal
transformation to the residuals as opposed to the adipo-
nectin values could have reintroduced inflation from the
covariates and identified false positive results.48 However,
examination of cohort-specific QQ plots, comparison of
models unadjusted and adjusted for BMI, and the resultsTfrom the collider bias analysis suggest any inflation is
unlikely.
To identify additional association signals at the 20 signif-
icant loci, we implemented conditional analyses and iden-
tified 3 additional, already established loci that harbored
multiple distinct variants associated with adiponectin:
ADIPOQ (9 signals; r2 ¼ 0.00–0.19), DNAH10-CCDC92
(2 signals; r2 ¼ 0.07; MIM: 614848), and SLC38A8 (2 sig-
nals; r2 ¼ 0.00) (Table S8; Figure S11). These results are
consistent with previous reports of multiple signals at
these loci for adiponectin and/or other cardiometabolic
traits.49,50 While the exome array-based analysis does not
fully characterize the number or identity of the signals
due to the relatively low density of analyzed variants, these
findings support the presence of multiple adiponectin as-
sociation signals at these loci.
Other Trait Associations
To further characterize the lead variants, we examined
their associations with a range of cardiometabolic traits,
including anthropometric, blood pressure, glycemic, and
lipid traits and T2D (Tables 2, S9, and S10). Of the nine
loci, six have previously shown a genome-wide significant
association (p < 5 3 108) with at least one additional
cardiometabolic trait: WHRadjBMI (four loci), HDL choles-
terol (three loci), fat free mass index (two loci), body fat
percentage (two loci), hip circumference (two loci), dia-
stolic blood pressure (two loci), systolic blood pressure
(one locus), hypertension (one locus), and BMI (one locus).
The adiponectin signal associated with the largest number
of other traits is SLC39A8, which also exhibited suggestive
pleiotropy in the collider bias analysis (Table S7). That lead
variant (p.Ala391Thr; rs13107325) has previously been
shown to associate with BMI, blood pressure traits, HDL,
other obesity-related traits, as well as Crohn disease and
schizophrenia.51 An additional PheWAS was performed
in all available traits, plasma proteins, and metabolites
(Tables S11 and S12). The additional trait associations
may suggest pleiotropic or mediating effects at these loci.
Extent of LD Surrounding Exome Array Signals
The identification of nonsynonymous variant associations
has the potential to pinpoint functional genes. However,
evidence of association is not sufficient to conclude that
these variants or genes have causal effects on trait levels.
To assess the potential role of variants at previously
unreported adiponectin loci, we assessed the LD with
neighboring variants using 1000 Genomes Phase 3 for
the European population to estimate the extent of the
locus and to identify additional candidate variants (r2 >
0.80) (Figures 1, 2, and S9; Table 2). Variants at four loci
(nearest genes KIF9, DALRD3, GIMAP7, and OPLAH) are
each part of wider LD blocks containing between 37 and
330 variants that span a distance of 35 to 819 kb including
multiple genes; three of these loci include nonsynony-
mous variants in more than one gene (Figures 1 and 2;
Table 2). For example, at the KIF9 locus (Figure 1, Table 2),he American Journal of Human Genetics 105, 1–14, July 3, 2019 5
Table 1. Adiponectin Loci in Sex-Combined and Sex-Specific Meta-analyses (Additive, adjBMI)
Variant Chr Position
Nearest
Gene Annotation EA EAF
Sex-Combined Women Men Sex Diff.
Effect p n Effect p n Effect p n pa
Loci Achieving Exome-wide Significance
rs2276853 3 47,282,303 KIF9 missense (p.Arg638Gly) A 0.594 0.033 3.35E08 65,521 0.039 1.98E06 31,788 0.029 4.18E04 33,733 4.17E01
rs3087866 3 49,054,692 DALRD3 missense (p.Gln299Arg) C 0.786 0.040 2.14E08 65,521 0.034 5.88E04 31,788 0.046 3.67E06 33,733 3.86E01
rs13133548 4 89,740,128 FAM13A intronic A 0.489 0.039 5.91E12 65,521 0.033 3.24E05 31,788 0.041 1.98E07 33,733 4.61E01
rs13107325 4 103,188,709 SLC39A8 missense (p.Ala391Thr) T 0.047 0.072 1.05E07 59,606 0.078 1.13E05 31,788 0.050 1.25E02 33,733 2.98E01
rs10282707 7 17,911,038 SNX13 intronic T 0.383 0.040 1.96E10 56,826 0.024 1.07E02 24,421 0.053 3.44E10 32,405 2.00E02
rs3735080 7 150,217,309 GIMAP7 missense (p.Arg83Cys) T 0.245 0.049 7.70E13 65,521 0.036 2.72E04 31,788 0.057 6.22E10 33,733 1.05E01
rs11993554 8 145,111,529 OPLAH synonymous (p.Phe612Phe) G 0.101 0.030 3.75E03 61,431 0.076 9.76E08 29,427 0.011 4.66E01 32,004 2.52E05
rs10861661 12 107,174,646 RIC8B intronic C 0.229 0.040 1.75E09 59,489 0.035 4.74E04 27,455 0.046 3.17E06 32,034 4.42E01
rs145119400 16 84,075,593 SLC38A8 missense (p.Pro57Leu) A 0.005 0.300 8.95E13 59,107 0.306 1.78E03 28,412 0.296 1.80E10 30,695 9.23E01
Previously Reported Loci Achieving Exome-wide Significance
rs2791552 1 219,652,033 LYPLAL1 intergenic C 0.676 0.676 1.75E14 55,387 0.055 8.97E09 26,391 0.054 7.16E09 28,996 9.68E01
rs2943641 2 227,093,745 IRS1 intergenic C 0.646 0.646 1.76E21 65,521 0.048 2.21E08 31,788 0.069 2.56E16 33,733 7.30E02
rs13303 3 52,558,008 STAB1 missense (p.Met2506Thr) C 0.569 0.569 2.69E21 61,431 0.061 8.28E13 29,427 0.060 4.74E12 32,004 9.53E01
rs17366568 3 186,570,453 ADIPOQ ncRNA/exonic A 0.118 0.118 1.43E145 51,153 0.216 1.61E64 31,788 0.239 5.86E89 25,849 1.97E01
rs4311394 5 53,300,662 ARL15 intronic G 0.257 0.257 1.68E10 59,931 0.046 1.54E06 28,914 0.044 3.84E06 31,017 9.13E01
rs7134375 12 20,473,758 PDE3A intergenic A 0.410 0.410 3.69E20 65,521 0.054 2.88E11 31,788 0.053 5.36E11 33,733 9.14E01
rs11057405 12 122,781,897 CLIP1 intronic A 0.086 0.086 2.90E14 65,521 0.092 1.74E10 31,788 0.068 1.24E06 33,733 2.29E01
rs11057353 12 124,265,687 DNAH10 missense (p.Ser167Pro) C 0.645 0.645 2.74E19 65,521 0.061 3.47E13 31,788 0.047 2.19E08 33,733 2.17E01
rs2925979 16 81,534,790 CMIP intronic C 0.693 0.693 1.38E37 61,801 0.093 6.72E26 29,767 0.072 1.91E16 32,034 8.80E02
rs3865188 16 82,650,717 CDH13 intergenic T 0.472 0.472 1.14E08 59,420 0.042 7.28E07 28,616 0.027 1.11E03 30,804 2.27E01
rs4805885 19 33,906,123 PEPD intronic C 0.603 0.603 2.85E25 61,431 0.076 4.63E19 29,427 0.052 5.77E28 32,004 5.20E02
Loci achieving exome-wide significance (p < 2E07) in sex-combined and/or sex-specific all-ancestry meta-analyses. Beta effect size from an additive model corresponding to the effect allele for inverse-normal transformed
adiponectin levels adjusted for age, BMI, and other study-specific covariates. The smallest p value for each variant is shown in bold. Physical positions based on hg19. Abbreviation: Chr, chromosome; EA, effect allele; EAF,
effect allele frequency; n, sample size.
aTest for sex difference; values significant at the table-wide Bonferroni threshold of 0.05/20 ¼ 2.5E03
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Figure 1. Loci in Adiponectin Exome-wide Meta-analysis Located within Broader Trait-Associated Regions
KIF9 locus (A) and GIMAP7 locus (B). Each point represents a variant in the meta-analysis, plotted with hg19 genomic position on the
x axis and p value (on a log10 scale) on the y axis. The upper plots show the current exome-wide meta-analysis, and the lower plots
show the genome-wide ADIPOGen consortium meta-analysis.14 In each plot, the lead variant identified in the exome array meta-anal-
ysis is represented in purple, and the color of all other variants indicate the LD with the lead variant in European ancestry haplotypes
from the 1000 Genomes Phase 3 reference panel. In both examples, the lead variant from the exome-wide analysis may not be the best
representative of the adiponectin-associated signal.
Please cite this article in press as: Spracklen et al., Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology, The
American Journal of Human Genetics (2019), https://doi.org/10.1016/j.ajhg.2019.05.002the lead variant, rs2276853, encodes KIF9 p.Arg638Gly.
However, 330 additional variants spanning nearly 600 kb
are in high LD with the lead variant (r2 > 0.80), including
nonsynonymous variants in four additional genes (SETD2
[MIM: 612778], SCAP [MIM: 601510], NBEAL2 [MIM:
614169], PTPN23 [MIM: 606584]). The wide LD regions
motivated further investigation of possible mechanisms
and gene(s) through which candidate variant(s) act to
affect adiponectin levels.
Most of the nonsynonymous variants identified in the
meta-analysis have low or inconsistent evidence of func-
tional consequences in algorithms, suggesting that other
variants may have functional effects (Table S13). Because
the exome array captures only a limited set of variants
and the extent of LD surrounding each of locus can be
vast, we further interrogated each locus to determine
whether the lead variant is the best representative of the as-
sociation signal. To do so, we examined the association re-
sults of the exome array loci within the ADIPOGen Con-
sortium genome-wide meta-analysis of adiponectin levels
(n ¼ 35,355; HapMap imputed).14 At six loci (KIF9, GI-
MAP7, DALRD3, RIC8B, SNX13, and FAM13A), a variant
other than the exome array lead variant showed a more
significant association with adiponectin (Figures 1 and 2,
Table 2). For example, at the KIF9 locus, genome-wide asso-
ciation results showed variants inmoderate LD (0.60< r2<T0.80) with the lead exome array variant that had stronger
association with adiponectin levels.14 These variants are
located near PTH1R (MIM: 168468), and reduced PTH1R
leads to increased adipocyte differentiation and higher adi-
ponectin levels (Table S14),52 suggesting PTH1R as a strong
candidate gene at this locus. A seventh locus, SLC38A8,
could not be compared to the genome-wide association
data because neither the lead variant nor either of the
two variants in strong LD (r2> 0.80) with it were evaluated
by ADIPOGen.14 These genome-wide analyses suggest that
the genes harboring the lead exome array variants may not
be the best candidate genes and that the association signals
may act via other variants and possibly other nearby genes
instead.
Comparison with eQTL Signals
To aid in the identification of candidate genes at the nine
previously unreported association signals, we examined
whether any of the variants associated with adiponectin
are colocalized (see Material andMethods) with expression
levels of nearby transcripts in subcutaneous or visceral
adipose tissue. For this analysis, we compared the pattern
of variant association with adiponectin levels to the
pattern of variant association in the expression quantita-
tive trait locus (eQTL) analysis in GTEx42 and the
METSIM study (Table S15).41 Two loci showed evidencehe American Journal of Human Genetics 105, 1–14, July 3, 2019 7
Figure 2. Subcutaneous Adipose eQTL for PRKAR2A Colocalizes
with the DALRD3 Adiponectin Exome-wide Locus
rs3087866 (purple diamond) shows the strongest association with
adiponectin levels in the exome-wide meta-analysis (top plot). In
the ADIPOGen genome-wide adiponectin meta-analysis (middle
plot),14 rs3087866 and 85 proxy variants (r2 > 0.80; 1000Gp3)
are nominally associated with adiponectin levels. The same vari-
ants exhibit the strongest association with expression of PRKAR2A
in subcutaneous adipose tissue (lower plot).41 Colocalized eQTL
signals are also observed for AMT and NICN1 (see Figure S12).
Each point represents a variant, plotted with hg19 genomic posi-
tion on the x axis and p value (on a log10 scale) on the y axis.
The color of all other variants indicates the LD with the lead
variant in European ancestry haplotypes from the 1000 Genomes
Phase 3 reference panel.
Please cite this article in press as: Spracklen et al., Exome-Derived Adiponectin-Associated Variants Implicate Obesity and Lipid Biology, The
American Journal of Human Genetics (2019), https://doi.org/10.1016/j.ajhg.2019.05.002of colocalized associations. The adiponectin-associated
variant rs13133548 is in high LD (r2 ¼ 0.95) with
rs72614904, the variant most strongly associated with
expression level of FAM13A (b ¼ 0.190, p ¼ 8.10 3 109);
alleles associated with lower adiponectin are associated
with higher FAM13A expression level. Consistent with
these associations, FAM13A has been shown to control8 The American Journal of Human Genetics 105, 1–14, July 3, 2019adipocyte lipolysis (Table S14).53 The next adiponectin-
associated variant rs3087866 is in high LD (r2 ¼ 0.99)
with rs6446200, the variant most strongly associated with
expression levels of PRKAR2A (MIM: 176910) (b ¼ 0.652,
p ¼ 5.79 3 1025; Figure 2), AMT (r2 ¼ 0.92, b ¼ 0.364,
p ¼ 1.14 3 108), and NICN1 (MIM: 611516) (r2 ¼ 0.90,
b ¼ 0.408, p ¼ 1.693 1011) (Figure S12). At this signal, al-
leles associated with lower adiponectin are associated with
higher PRKAR2A and NICN1 expression level, but lower
AMT (MIM: 238310) expression level. The strongest eQTL
association signal is with PRKAR2A, which encodes a sub-
unit of cAMP-dependent protein kinase, an essential regu-
lator of lipid and glucose metabolism that plays a role in
energy homeostasis.54 Although the exome array variants
may not be the best representative variant for these associ-
ation signals, the LD between the exome array variants and
the lead eQTL variants is strong, suggesting that FAM13A,
PRKAR2A, AMT, and NICN1 are plausible candidate genes
for regulatory effects at these loci.
Candidate Pathways
To further characterize the biological processes and candi-
date pathways enriched within the identified adiponectin-
associated loci, we performed gene set enrichment
analyses using PASCAL and EC-DEPICT.26,43,45 The
PASCAL analyses assuming single association signals
from each locus (MAX score) showed significant (p < 5 3
105) evidence for enrichment in gene sets for the adipo-
cyte differentiation-related ATXN1 protein-protein inter-
action sub-network55 (Tables S16A, S16B, and S17), and
the PASCAL analyses that considered multiple association
signals from the same loci (SUM score) provided additional
evidence for enrichment in gene sets for abnormal white
adipose tissue physiology, decreased gonadal fat pad
weight, and the adipogenesis-related NR3C1 protein-pro-
tein interaction sub-network (Tables S16C, S16D, and
S17).56 None of the gene sets from EC-DEPICT achieved
statistical significance (FDR< 0.05), possibly due to sample
size and the number of loci detected (especially for the
analysis restricted to low-frequency and rare variants
[MAF < 5%]) (Tables S18A and S18B). The enriched pro-
cesses obtained with these approaches suggest that the
adiponectin association signals may alter adipose tissue-
and obesity-related pathways.
Discussion
This exome-array based meta-analysis of 265,780 variants
in up to 67,739 individuals from four different ancestries
identified 30 distinct signals in 20 loci associated with
circulating adiponectin levels, including nine loci previ-
ously not reported to be associated with adiponectin.
Two of the independent signals are located in regions
that exhibit extensive LD, and comparison of lead exome
array variants to the patterns of association in the
previously performed, smaller ADIPOGen GWAS data-
set14 suggests the possible contribution of noncoding
Table 2. Biological Candidate Genes at Previously Unreported Adiponectin-Associated Loci
Lead
Variant EAF
Nearest
Gene
n Variants
r2 R 0.80
(Distance kb)
n Variants
r2 R 0.60
(Distance kb)
Function/
Nonsynonymous
Variants (r2 > 0.8)
Adipose eQTL
Gene
(p < 5 3 108)
Other Trait
Associations
(p < 1 3 104)
Literature
Candidate
rs2276853 0.59 KIF9 330 (597 kb) 353 (597 kb) KIF9 (p.Arg638Gly)*;
SETD2 (p.Pro1918His);
SCAP (p.Val543Ile);
NBEAL2 (p.Arg511Gly);
PTPN23 (p.Ala818Thr)
– WHRadjBMI,
adiponectin, T2D
PTH1R
rs3087866 0.79 DALRD3 73 (819 kb) 210 (833 kb) DALRD3 (p.Gln299Arg)* AMT, NICN1,
PRKAR2A,
QRICH1
FFMI, WHRadjBMI,
Adiponectin,
Menarche, T2D
PRKAR2A
rs13133548 0.49 FAM13A 41 (35 kb) 54 (35 kb) – FAM13A BF%, HC, HDL,
WHRadjBMI,
Adiponectin,
BMI, T2D, TG
FAM13A
rs13107325 0.05 SLC39A8 3 (51 kb) 4 (196 kb) SLC39A8 (p.Ala391Thr)* – BMI, BF%, DBP,
FFMI, HC, HDL,
HTN, SBP, WC,
WHRadjBMI,
Adiponectin, TG
SLC39A8
rs10282707 0.38 SNX13 9 (104 kb) 16 (130 kb) – – HDL, TC HDAC9
rs3735080 0.24 GIMAP7 278 (119 kb) 294 (146 kb) GIMAP7 (p.Arg83Cys)*;
GIMAP6 (p.Gly241Ser)
– DBP, FFMI, HTN,
SBP
REPIN1;
RARRES2
rs11993554 0.10 OPLAH 37 (57 kb) 122 (107 kb) OPLAH (p.Phe612Phe*,
p.Arg31Gln, p.Val340Ile,
p.Ser284Arg); EPPK1
(p.Arg936Trp)
– WHRadjBMI MAF1
rs10861661 0.23 RIC8B 14 (134 kb) 16 (134 kb) – – WHRadjBMI,
HDL, TG, HC
CRY1
rs145119400 0.005 SLC38A8 2 (257 kb) 2 (257 kb) SLC38A8 (p.Pro57Leu)* – – CDH13;
MBTPS1
Biological candidate genes at each of the loci previously not shown to be association with adiponectin. Number of variants in moderate to strong linkage disequi-
librium and the distance spanned obtained using data from 1000 Genomes Phase 3 and build hg19 (LDLink). Nonsynonymous variants noted with an asterisk (*)
are the lead variants identified at each locus. eQTLs were identified in METSIM subcutaneous adipose and/or GTEx subcutaneous or visceral adipose tissues (see
Table S15). Other trait associations were identified from available summary statistics from the ADIPOGen, DIAGRAM, GIANT, and GLGC consortia, along with the
UK Biobank (see Tables S9–S11). Abbreviations: BMI, bodymass index; BF%, body fat percentage; DBP, diastolic blood pressure; FFMI, fat free mass index; HC, hip
circumference; HDL, high density lipoprotein cholesterol; HTN, hypertension; Menarche, age at menarche; SBP, systolic blood pressure; WC, waist circumference;
WHRadjBMI, waist-hip-ratio adjusted for BMI.
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colocalizations and evaluation of gene functions helped
detect potential genes and mechanisms through which
the variantsmay act to affect adiponectin levels. Candidate
genes include FAM13A, SLC39A8, PRKAR2A, PTH1R, and
HDAC9. Eight of the association signals have been
found to be associated with other obesity and lipid traits;
the evidence of association with adiponectin levels also
guides interpretation of genes and mechanisms for these
traits.
Once an association with a nonsynonymous variant is
detected, it is simple to hypothesize a causal connection
between the variant, the gene in which it is located, and
the examined phenotype. We demonstrate that this
assumption is often inaccurate, particularly with regards
to common nonsynonymous variants identified through
an exome array analysis. For example, the common
(MAF ¼ 0.41), adiponectin-associated variant, rs2276853,
encodes missense variant p.Arg638Gly in KIF9, kinesin
family member 9, a regulator of spindle dynamics localized
to the nuclear envelope that is essential for mitosis.57TExamination of the surrounding wide LD region using
GWAS data from the previous ADIPOGen study14 showed
that moderately correlated variants 300 kb upstream near
PTH1R, parathyroid hormone receptor 1, exhibited a
more significant association with adiponectin levels.
Reduced levels of PTH1R lead to increased adipocyte
differentiation into mature adipocytes responsible for
adiponectin secretion,52 suggesting that the variant alleles
may act to reduce PTH1R expression, leading to
higher adipocyte differentiation and higher adiponectin
levels. PTH1R has also been studied extensively in bone
marrow, which has been shown to secrete higher levels
of adiponectin than white adipose tissue,58 suggesting
that the effect of this locus on adiponectin levels might
be mediated by secretion of adiponectin from the bone
marrow.
Another example of a nonsynonymous variant repre-
senting a potential false lead for causality with adiponectin
is rs3087866 (p.Gln299Arg; MAF¼ 0.21) located within an
exon ofDALRD3, a locus that has also been associated with
central adiposity.36 While the exact function is unknown,he American Journal of Human Genetics 105, 1–14, July 3, 2019 9
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binding domain, similar to that of tRNA synthetases. At
this locus, however, the strongest colocalized eQTL is for
PRKAR2A, which encodes a regulatory subunit of protein
kinase A. Prkar2a knockout mice weigh less than wild-
type littermates and are resistant to diet-induced obesity,
glucose intolerance, and fatty liver.59 At the human
adiponectin-associated locus, the rs3087866-C allele was
associated with decreased adiponectin levels and decreased
adipose PRKAR2A expression. This observation is consis-
tent with the smaller adipose tissue depots observed
in knockout mice59 and supports the possibility that
PRKAR2A contributes to the associations with both adipo-
nectin and central adiposity. The other colocalized eQTLs
for AMT and NICN1 at this locus were weaker and less
clearly relevant to adipose biology.
Exome arrays contain variants with sparse coverage, and
trait-associated variants can be located hundreds of kilo-
bases from their target genes. Here, rs10282707 (MAF ¼
0.38), previously associated with HDL cholesterol,25 is
located within an intron of SNX13, sorting nexin 13.
This gene belongs to the sorting nexin family, a G protein
signaling regulator family ofmolecules that are involved in
intracellular trafficking and regulate G alpha subunits of
heterotrimeric G proteins. Located 200 kb downstream of
SNX13, HDAC9 (MIM: 606543) encodes histone deacety-
lase 9, which alters chromosome structure and affects
transcription factor access to DNA. HDAC9 has been
shown to be a negative regulator of adipocyte differentia-
tion.60 Higher levels of Hdac9 prevented adipocyte differ-
entiation, and knockout of Hdac9 in mice protected from
adipose tissue dysfunction and systemic metabolic disease
during high fat feeding.61 In humans, the allele associated
with higher adiponectin and lower HDL cholesterol levels
may act by reducing HDAC9 expression or function. The
GWAS data helped guide interpretation of candidate genes
at this locus.
Using the context of regional LD and existing adiponec-
tin GWAS data from ADIPOGen14 is not sufficient for
mapping of multiple association signals at a locus. For
example, CDH13 encodes an extracellular cadherin-13 re-
ceptor that binds to adiponectin,62 and variants near
CDH13 are well established to show very strong adiponec-
tin association.14,19 The strongest adiponectin-associated
variant near CDH13 from the exome array analysis was
rs3865188, located near the CDH13 promoter, although
rs3865188 is in low LD (r2 ¼ 0.16) with the lead variant in
the genome-wide data, rs12051272.14 The exome array
analysis also identified an adiponectin-associated variant
(rs145119400, MAF ¼ 0.005) nearly 1.5 Mb away within
SLC38A8, and association analysis conditioning on
rs145119400 identified yet another signal 260 kbupstream,
within an exon of CDH13 (rs186440718, MAF ¼ 0.003).
Neither rs145119400 nor rs186440718 are available in the
ADIPOGen consortium data, and rs145119400 is present
in only one person in the 1000 Genomes Phase 3 reference
panel. Thus, we were not able to determine the number of10 The American Journal of Human Genetics 105, 1–14, July 3, 2019association signals, nor whether these three variants are
all tagging the established CDH13 association signals, nor
whether rs145119400 and SLC38A8 represent a distinct as-
sociation signal and candidate gene for adiponectin
biology. Future genome-wide association data in larger
datasets with dense marker maps will provide valuable op-
portunities to perform more detailed genomic and fine-
mapping analyses to identify potential candidate genes
and pathways.
Identification of the gene(s) underlying genetic associa-
tion signals is imperative to translate associated variants to
biological processes. One method that has proven useful
for the prediction of candidate functional genes is with the
detection of colocalized eQTLs in relevant tissues.63–65How-
ever, determination of colocalized GWASs and eQTL loci re-
quires accurate identification of the variants most strongly
associated with the phenotype and gene expression levels
in both sets of data. With the sparse coverage of variants in
the exome array, other untested variants in low tomoderate
LDwith the leadexomevariantmay exhibit stronger trait as-
sociations, leading to false identification of a colocalized
eQTL or, more likely, missing a colocalized eQTL signal.
Larger and more diverse eQTL studies including both sexes
and broader ancestry could help identify additional colocal-
ized association signals.While exome array data canbevalu-
able in identifying low-frequency or rare variants present on
the array that are often poorly imputed from genotyping ar-
rays, cautionshouldbeused in translatingassociation results
into candidate functional variants and genes.
Taken together, our results emphasize the value of using
exome array analysis for identification of both coding and
noncoding signals in discovery of candidate genes relevant
for lipid andobesity biology.However, use of genome-wide
association data to characterize exome array signals facili-
tated detection of the LD structure in the association
signals, a few of which suggested that more strongly asso-
ciated variants exist outside exons. As such, caution should
be used in the interpretation of results from both exome
array and exome-sequencing studies.66 Future GWASs in
larger sample sizes will be valuable to validate these results
and extend them to additional loci and genes that influ-
ence cardiometabolic traits and diseases.Data Availability
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